Full text is available at the source.
Abstract
A clinical roadmap for integrating adjunctive metabolic therapies into type 1 diabetes care is proposed.
- Cardiometabolic risk, weight gain, and glycemic variability are ongoing challenges for those with type 1 diabetes.
- Incretin-based therapies and amylin analogs may serve as initial, effective options for metabolic management.
- Sodium-glucose linked transporter inhibitors could be safely utilized with the aid of continuous ketone monitoring.
- Emerging therapeutic targets include glucagon modulation and fibroblast growth factor 21 analogs.
Simplified